Considering BCG vaccination to reduce the impact of COVID-19
Nigel Curtis
Annie Sparrow
Tedros A Ghebreyesus
Mihai G Netea
Published:April 30, 2020DOI:https://doi.org/10.1016/S0140-6736(20)31025-4
In addition to its specific effect against tuberculosis, the BCG vaccine has beneficial nonspecific (off-target) effects on the immune system that protect against a wide range of other infections and are used routinely to treat bladder cancer.1, 2 This has led to the suggestion that vaccination with BCG might have a role in protecting health-care workers and other vulnerable individuals against severe coronavirus disease 2019 (COVID-19).
Randomised controlled trials have provided evidence that the BCG vaccine's immunomodulatory properties can protect against respiratory infections. In Guinea-Bissau, a high-mortality setting, BCG-Danish reduced all-cause neonatal mortality by 38% (95% CI 17–54), mainly because there were fewer deaths from pneumonia and sepsis.3 In South Africa, BCG-Danish reduced respiratory tract infections by 73% (95% CI 39–88) in adolescents.4